Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
---|---|
Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ClinicalTrials.gov Identifier: | NCT00090584 |
The primary aim of this study is to test if the addition of behavioral treatment to drug therapy for the treatment of urge incontinence will increase the number of patients who can discontinue drug therapy and sustain a significant reduction of incontinence.
Condition | Intervention | Phase |
---|---|---|
Urinary Incontinence |
Drug: Tolterodine Behavioral: Combination Drug (tolterodine) and Behavior Treatment |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Behavior Enhances Drug Reduction of Incontinence |
Ages Eligible for Study: | 21 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion:
Exclusion:
United States, Alabama | |
University of Alabama | |
Birmingham, Alabama, United States, 35233 | |
United States, California | |
University of California | |
San Diego, California, United States, 92103 | |
United States, Illinois | |
Loyola University Medical Center | |
Maywood, Illinois, United States, 60153 | |
United States, Maryland | |
University of Maryland | |
Baltimore, Maryland, United States, 21201 | |
United States, Michigan | |
Oakwood Hospital and Medical Center | |
Royal Oak, Michigan, United States, 48123 | |
United States, Pennsylvania | |
University of Pittsburgh | |
Pittsburgh, Pennsylvania, United States, 15213 | |
United States, Texas | |
University of Texas Southwestern | |
Dallas, Texas, United States, 75390 | |
University of Texas Health Sciences Center | |
San Antonio, Texas, United States, 78229 | |
United States, Utah | |
University of Utah | |
Salt Lake City, Utah, United States, 84132 |
Study Chair: | William D Steers, M.D. | University of Virginia |
Responsible Party: | NIDDK ( Debuene Chang, MD Project Officer ) |
Study ID Numbers: | BE-DRI |
Study First Received: | August 27, 2004 |
Last Updated: | December 21, 2007 |
ClinicalTrials.gov Identifier: | NCT00090584 |
Health Authority: | United States: Federal Government |
Urge urinary incontinence Drug/Behavior treatment |
Signs and Symptoms Urologic Diseases Urination Disorders |
Urinary Incontinence Urinary Incontinence, Urge Tolterodine |
Muscarinic Antagonists Urological Manifestations Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
Cholinergic Antagonists Physiological Effects of Drugs Cholinergic Agents Pharmacologic Actions |